Research & Innovation - Participant Portal

Personalising health and care

H2020-PHC-2015-two-stageSub call of: H2020-PHC-2014-2015
Opening Date 30-07-2014 Deadline Date 14-10-2014 17:00:00 (Brussels local time)
Publication date 23-07-2014 Total Call Budget €306,000,000
Stage 2 21-04-2015 17:00:00 (Brussels local time)
Programme Horizon 2020
Status Closed Main Pillar Societal Challenges
OJ reference OJ C 361 of 11 December 2013

Topic: Piloting personalised medicine in health and care systems PHC-24-2015

Specific challenge: Personalised medicine[1] has the potential to respond to, amongst others, the increasing burden of chronic disease and the complexity of co-morbidities and in doing so contribute to the sustainability of health and care systems.


If this potential is to be realised at a larger scale it must first be demonstrated in terms of sustainable benefits, and as a new model of care organisation. Demonstration is however complicated by the diversity of European Union health systems.

Scope: Pilots of new models of care, based on the concept of personalised medicine should be conducted in existing health care environments and should take into account Europe's (national and regional) diversity in health system organisation.


Proposals should ensure coordination with national, regional or local authorities engaging in health sector reform, with the design of new models taking into account the views of other relevant stakeholders, including policy makers and citizens. Behavioural, ethical, legal, social implications as well as the gender dimension should be addressed.


The health, economic and social impact of the implementation of these pilots on individual patients, whole or stratified population groups, and their impact at the level of health care systems should be assessed. The organisational and resource requirements of the piloted models (data, personnel and financing) should be tracked, providing evidence on methods of implementation and benefits of reform while ensuring safety, equity and cost effectiveness.  Appropriate measures for knowledge transfer and capacity building should be put in place.


The Commission considers that proposals requesting a contribution from the EU of between EUR 12 and 15 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Expected impact: On the basis of quantitative and qualitative indicators, evidence for a validated model of organisation of care based on the concept of personalised medicine should be produced, to be used by policy makers and decision makers in making improvements to health and care systems.

Type of action: Research and innovation actions

[1] Personalised medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention

Please read carefully all provisions below before the preparation of your application.

  1. List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
  2. Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
  3. Evaluation

    3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme, with the following exceptions
    The thresholds for each criterion at stage 1 (of a two stage process) will be 4 and 4. The cumulative threshold will be 8.5.
    The thresholds for each criterion at stage 2 (of a two stage process) will be 4, 4 and 3. The cumulative threshold will be 12.
    If a proposal fails to achieve the threshold for a criterion at any stage, the evaluation of the proposal will be stopped.
    The median of individual evaluator scores may be used at stage 1 to determine the consensus score and when appropriate, the resulting consensus report may comprise elements of these individual reports, or standard phrases representative thereof.
    The page limit for stage 1 proposals is 7 pages (including the title page).

    3.2 Guide to the submission and evaluation process
  4. Proposal page limits and layout: Please refer to Part B of the standard proposal template.
  5. Indicative timetable for evaluation and grant agreement:
    Information on the outcome of two-stage evaluation: maximum 5 months from the final date for submission.
    Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
  6. Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:

    Research and Innovation Action:

    Specific provisions and funding rates
    Annotated Model Grant Agreement

    For information, a pdf. template of the evaluation form for this topic is available on the call page under call documents. In addition, to be consulted on the same page a specific template for essential information for clinical trials/studies/investigations is available.
  7. Additional provisions:

    Horizon 2020 budget flexibility

    Classified information

  8. Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.


Additional documents

You can download the same documents as one zip file from the call page

  • Legal basis - Specific Programme H2020 en
  • WP H2020 - 1. Introduction en
  • WP H2020 - 8. Health, demographic change and wellbeing en
  • Legal basis - Framework Programme H2020 en
  • Legal basis - Rules for Participation en
  • WP H2020 - 19. General Annexes en
  • FAQ en
  • Essential information for clinical studies en
  • Part B Template section 1-3 en
  • Part B Template section 4-5 en

No submission system is open for this topic.